{"id":576,"date":"2015-05-05T12:19:00","date_gmt":"2015-05-05T12:19:00","guid":{"rendered":"http:\/\/bxta-staging.website\/?p=576"},"modified":"2021-12-17T10:13:27","modified_gmt":"2021-12-17T10:13:27","slug":"ascende-rt-study","status":"publish","type":"post","link":"https:\/\/bxta.com\/de\/ascende-rt-study\/","title":{"rendered":"ASCENDE-RT-Studie: Die \u00dcberlebenschance von Prostatakrebspatienten mit mittlerem und hohem Risiko ist mit Brachytherapie-Seeds doppelt so hoch"},"content":{"rendered":"
\n

ASCENDE-RT-Studie: Die \u00dcberlebenschance von Prostatakrebspatienten mit mittlerem und hohem Risiko ist mit Brachytherapie-Seeds doppelt so hoch<\/strong><\/h3><\/div><\/div>\n\n\n\n
\"\"<\/figure>\n\n\n\n

Das in Gro\u00dfbritannien ans\u00e4ssige Brachytherapie-Unternehmen BXTAccelyon Limited, das Krankenh\u00e4user und Kliniken weltweit mit Seeds, geladenen Nadelsystemen und dazugeh\u00f6rigem Zubeh\u00f6r und Ger\u00e4ten beliefert, hat zu einer baldigen \u00dcberpr\u00fcfung der Verf\u00fcgbarkeit der Seed-Brachytherapie f\u00fcr Patienten mit mittlerem und hohem Prostatakrebsrisiko aufgerufen. Dies erfolgte im Anschluss an die auf der j\u00fcngsten ESTRO-Konferenz in Barcelona pr\u00e4sentierten Daten der ASCENDE-RT-Studie zur Erh\u00f6hung der Dosis der Strahlentherapie f\u00fcr diese Patienten.<\/p>\n\n\n\n

Brachytherapie mit niedriger Dosisrate (Low Dose Rate, LDR) ist eine Form der Strahlentherapie, bei der winzige radioaktive \u201eSeeds\u201c direkt in die Prostata implantiert werden. Die ASCENDE-RT-Studie aus Kanada ist eine randomisierte Studie, welche die Anwendung der Dosis-eskalierten externen Strahlentherapie (DE-EBRT) mit der Brachytherapie mit niedriger Dosisrate (LDR-B) bei M\u00e4nnern mit mittlerem und hohem Prostatakrebsrisiko vergleicht. Insgesamt ergab die Studie eine 50-prozentige Verringerung des biochemischen R\u00fcckfalls bei der Verwendung von LDR-B in Verbindung mit Hormonen und Strahlentherapie des ganzen Beckens im Vergleich zur Verwendung von DE-EBRT mit denselben Behandlungen bei Patienten, die den beiden Behandlungsformen zuf\u00e4llig zugeteilt wurden.<\/p>\n\n\n\n

Im Vereinigten K\u00f6nigreich und in Irland werden j\u00e4hrlich etwa 45.000 1,2 Prostatakarzinom-Neuerkrankungen diagnostiziert, und bei zwei Dritteln dieser Patienten befindet sich die Erkrankung im Fr\u00fchstadium, die f\u00fcr eine LDR-Brachytherapie-Behandlung geeignet ist. Gegenw\u00e4rtig werden j\u00e4hrlich \u00fcber 1.500 Patienten in 36 Zentren im Vereinigten K\u00f6nigreich und in Irland mit Brachytherapie-Seeds behandelt 3. In Australien und Neuseeland werden j\u00e4hrlich etwa 23.000 4,5 Prostatakarzinom-Neuerkrankungen diagnostiziert, und bei zwei Dritteln dieser Patienten befindet sich die Erkrankung im Fr\u00fchstadium, die f\u00fcr eine LDR-Brachytherapie-Behandlung geeignet ist. 1,2<\/sup> new prostate cancer cases are diagnosed annually and two-thirds of these patients have early stage disease which is suitable for LDR brachytherapy treatment. Currently, over 1,500 patients receive brachytherapy seed treatment annually at 36 centres in the UK & Ireland3. In Australia and New Zealand around 23,000 4,5<\/sup> new prostate cancer cases are diagnosed annually and over two-thirds of these patients have early stage disease which is suitable for LDR brachytherapy treatment.<\/p>\n\n\n\n

Saheed Rashid, Gesch\u00e4ftsf\u00fchrer von BXTAccelyon, hierzu: \u201eDiese Art Information kann Klinik\u00e4rzten und Beauftragten im Gesundheitswesen dabei helfen, die besten Behandlungen f\u00fcr Patienten mit Prostatakrebs zu ermitteln und ihnen anzubieten. Die Studie ist extrem wertvoll, da sie deutlich macht, dass eine \u00c4nderung der klinischen Praxis notwendig ist, um M\u00e4nnern mit dieser Art Krankheit Zugang zu einer Behandlung zu erm\u00f6glichen, die ihnen eine f\u00fcnfzigprozentig bessere Chance gibt, langfristig krankheitsfrei zu bleiben. Abgesehen von der Einfachheit und den kostensparenden Vorteilen der Seed-Brachytherapie als Behandlungsoption ist diese Studie auch aufgrund der \u201eFreisetzung\u201c wertvoller Zeit an den f\u00fcr die Strahlentherapie verwendeten Maschinen von enormer Bedeutung, und zwar nicht nur f\u00fcr Prostatakrebspatienten, sondern auch f\u00fcr Patienten mit anderen Krebsarten, die oft lange auf eine Behandlung an den gleichen Maschinen warten m\u00fcssen.\u201c<\/p>\n\n\n\n

\n
<\/div>
Ascende-RT Data Sheet (EN)<\/a><\/a><\/div><\/div><\/div>\n\n\n\n
<\/div>
Ascende-RT Data Sheet (NL)<\/a><\/a><\/div><\/div><\/div>\n<\/div><\/div><\/div>\n\n\n\n

F\u00fcr mehr Informationen wenden Sie sich bitte an:<\/p>\n\n\n\n

Saheed Rashid (Gesch\u00e4ftsf\u00fchrer)
E: saheed.rashid@bxta.com
T: +44(0)7979-327526
W: www.bxta.com<\/p>\n\n\n\n

Quellenangaben:
1. Office of national statistics: Cancer registry statistics \u2013 England, Scotland, Wales & Northern Ireland UK Ref 1-6
2. 6. National Cancer Registry Ireland: Cancer Trends
3. wwwprostatebrachytherapyinfo.net UK and Ireland Brachytherapy Centres and Procedure numbers.
4. Australian Insititute of Health and Welfare Cancer in Australia 2012 and Cancer Incidence Projections
5. Inquiry into early detection and treatment of prostate cancer Report to Health Committee NZ House of Representatives July 2011, Cancer Statistics,www.health.govt.nz\/nz-health-statistics\/publications-data-sets-and-stats\/cancer-data-and-stats<\/p>\n\n\n\n

Quellenangaben:
BXTAccelyon Limited ist ein britisches Unternehmen mit eingetragenem Gesch\u00e4ftssitz in The Coach House, Grenville Court, Britwell Road, Burnham SL1 8DF UK.<\/p>\n<\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":10,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[4],"tags":[],"class_list":["post-576","post","type-post","status-publish","format-standard","hentry","category-news"],"acf":[],"yoast_head":"\nASCENDE RT study: intermediate and high risk prostate cancer patients have double the survival chance with brachytherapy seeds - BXTA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bxta.com\/de\/ascende-rt-study\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASCENDE RT study: intermediate and high risk prostate cancer patients have double the survival chance with brachytherapy seeds - BXTA\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bxta.com\/de\/ascende-rt-study\/\" \/>\n<meta property=\"og:site_name\" content=\"BXTA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/bxtainternational\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-05-05T12:19:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-12-17T10:13:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bxta-staging.website\/wp-content\/uploads\/2020\/06\/ezgif.com-webp-to-jpg-1.jpg\" \/>\n<meta name=\"author\" content=\"Marketing BXTA\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@BXTA_\" \/>\n<meta name=\"twitter:site\" content=\"@BXTA_\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Marketing BXTA\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/bxta.com\\\/ascende-rt-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/ascende-rt-study\\\/\"},\"author\":{\"name\":\"Marketing BXTA\",\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#\\\/schema\\\/person\\\/be7f4368cd4f7e11918870d00223473a\"},\"headline\":\"ASCENDE RT study: intermediate and high risk prostate cancer patients have double the survival chance with brachytherapy seeds\",\"datePublished\":\"2015-05-05T12:19:00+00:00\",\"dateModified\":\"2021-12-17T10:13:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/ascende-rt-study\\\/\"},\"wordCount\":528,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/ascende-rt-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/bxta-staging.website\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/ezgif.com-webp-to-jpg-1.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/bxta.com\\\/ascende-rt-study\\\/\",\"url\":\"https:\\\/\\\/bxta.com\\\/ascende-rt-study\\\/\",\"name\":\"ASCENDE RT study: intermediate and high risk prostate cancer patients have double the survival chance with brachytherapy seeds - BXTA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/ascende-rt-study\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/ascende-rt-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/bxta-staging.website\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/ezgif.com-webp-to-jpg-1.jpg\",\"datePublished\":\"2015-05-05T12:19:00+00:00\",\"dateModified\":\"2021-12-17T10:13:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/ascende-rt-study\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/bxta.com\\\/ascende-rt-study\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/bxta.com\\\/ascende-rt-study\\\/#primaryimage\",\"url\":\"https:\\\/\\\/bxta-staging.website\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/ezgif.com-webp-to-jpg-1.jpg\",\"contentUrl\":\"https:\\\/\\\/bxta-staging.website\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/ezgif.com-webp-to-jpg-1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/bxta.com\\\/ascende-rt-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/bxta.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASCENDE RT study: intermediate and high risk prostate cancer patients have double the survival chance with brachytherapy seeds\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#website\",\"url\":\"https:\\\/\\\/bxta.com\\\/uk\\\/\",\"name\":\"BXTA\",\"description\":\"Let\u2019s tackle Prostate Cancer together | BXTA\",\"publisher\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/bxta.com\\\/uk\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#organization\",\"name\":\"BXTA\",\"url\":\"https:\\\/\\\/bxta.com\\\/uk\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/bxta-staging.s3.eu-west-2.amazonaws.com\\\/app\\\/uploads\\\/2021\\\/09\\\/07212056\\\/BXTA-Logo.png\",\"contentUrl\":\"https:\\\/\\\/bxta-staging.s3.eu-west-2.amazonaws.com\\\/app\\\/uploads\\\/2021\\\/09\\\/07212056\\\/BXTA-Logo.png\",\"width\":600,\"height\":373,\"caption\":\"BXTA\"},\"image\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/bxtainternational\\\/\",\"https:\\\/\\\/x.com\\\/BXTA_\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/bxtaccelyon\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCkTU9L10CS5c1eWtGiMZ7gw\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#\\\/schema\\\/person\\\/be7f4368cd4f7e11918870d00223473a\",\"name\":\"Marketing BXTA\",\"url\":\"https:\\\/\\\/bxta.com\\\/de\\\/author\\\/marketingbxta\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASCENDE RT study: intermediate and high risk prostate cancer patients have double the survival chance with brachytherapy seeds - BXTA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bxta.com\/de\/ascende-rt-study\/","og_locale":"de_DE","og_type":"article","og_title":"ASCENDE RT study: intermediate and high risk prostate cancer patients have double the survival chance with brachytherapy seeds - BXTA","og_url":"https:\/\/bxta.com\/de\/ascende-rt-study\/","og_site_name":"BXTA","article_publisher":"https:\/\/www.facebook.com\/bxtainternational\/","article_published_time":"2015-05-05T12:19:00+00:00","article_modified_time":"2021-12-17T10:13:27+00:00","og_image":[{"url":"https:\/\/bxta-staging.website\/wp-content\/uploads\/2020\/06\/ezgif.com-webp-to-jpg-1.jpg","type":"","width":"","height":""}],"author":"Marketing BXTA","twitter_card":"summary_large_image","twitter_creator":"@BXTA_","twitter_site":"@BXTA_","twitter_misc":{"Verfasst von":"Marketing BXTA","Gesch\u00e4tzte Lesezeit":"3\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bxta.com\/ascende-rt-study\/#article","isPartOf":{"@id":"https:\/\/bxta.com\/ascende-rt-study\/"},"author":{"name":"Marketing BXTA","@id":"https:\/\/bxta.com\/uk\/#\/schema\/person\/be7f4368cd4f7e11918870d00223473a"},"headline":"ASCENDE RT study: intermediate and high risk prostate cancer patients have double the survival chance with brachytherapy seeds","datePublished":"2015-05-05T12:19:00+00:00","dateModified":"2021-12-17T10:13:27+00:00","mainEntityOfPage":{"@id":"https:\/\/bxta.com\/ascende-rt-study\/"},"wordCount":528,"commentCount":0,"publisher":{"@id":"https:\/\/bxta.com\/uk\/#organization"},"image":{"@id":"https:\/\/bxta.com\/ascende-rt-study\/#primaryimage"},"thumbnailUrl":"https:\/\/bxta-staging.website\/wp-content\/uploads\/2020\/06\/ezgif.com-webp-to-jpg-1.jpg","articleSection":["News"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/bxta.com\/ascende-rt-study\/","url":"https:\/\/bxta.com\/ascende-rt-study\/","name":"ASCENDE RT study: intermediate and high risk prostate cancer patients have double the survival chance with brachytherapy seeds - BXTA","isPartOf":{"@id":"https:\/\/bxta.com\/uk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/bxta.com\/ascende-rt-study\/#primaryimage"},"image":{"@id":"https:\/\/bxta.com\/ascende-rt-study\/#primaryimage"},"thumbnailUrl":"https:\/\/bxta-staging.website\/wp-content\/uploads\/2020\/06\/ezgif.com-webp-to-jpg-1.jpg","datePublished":"2015-05-05T12:19:00+00:00","dateModified":"2021-12-17T10:13:27+00:00","breadcrumb":{"@id":"https:\/\/bxta.com\/ascende-rt-study\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bxta.com\/ascende-rt-study\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/bxta.com\/ascende-rt-study\/#primaryimage","url":"https:\/\/bxta-staging.website\/wp-content\/uploads\/2020\/06\/ezgif.com-webp-to-jpg-1.jpg","contentUrl":"https:\/\/bxta-staging.website\/wp-content\/uploads\/2020\/06\/ezgif.com-webp-to-jpg-1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/bxta.com\/ascende-rt-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bxta.com\/"},{"@type":"ListItem","position":2,"name":"ASCENDE RT study: intermediate and high risk prostate cancer patients have double the survival chance with brachytherapy seeds"}]},{"@type":"WebSite","@id":"https:\/\/bxta.com\/uk\/#website","url":"https:\/\/bxta.com\/uk\/","name":"BXTA","description":"Let\u2019s tackle Prostate Cancer together | BXTA","publisher":{"@id":"https:\/\/bxta.com\/uk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bxta.com\/uk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/bxta.com\/uk\/#organization","name":"BXTA","url":"https:\/\/bxta.com\/uk\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/bxta.com\/uk\/#\/schema\/logo\/image\/","url":"https:\/\/bxta-staging.s3.eu-west-2.amazonaws.com\/app\/uploads\/2021\/09\/07212056\/BXTA-Logo.png","contentUrl":"https:\/\/bxta-staging.s3.eu-west-2.amazonaws.com\/app\/uploads\/2021\/09\/07212056\/BXTA-Logo.png","width":600,"height":373,"caption":"BXTA"},"image":{"@id":"https:\/\/bxta.com\/uk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/bxtainternational\/","https:\/\/x.com\/BXTA_","https:\/\/www.linkedin.com\/company\/bxtaccelyon","https:\/\/www.youtube.com\/channel\/UCkTU9L10CS5c1eWtGiMZ7gw"]},{"@type":"Person","@id":"https:\/\/bxta.com\/uk\/#\/schema\/person\/be7f4368cd4f7e11918870d00223473a","name":"Marketing BXTA","url":"https:\/\/bxta.com\/de\/author\/marketingbxta\/"}]}},"_links":{"self":[{"href":"https:\/\/bxta.com\/de\/wp-json\/wp\/v2\/posts\/576","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bxta.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bxta.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bxta.com\/de\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/bxta.com\/de\/wp-json\/wp\/v2\/comments?post=576"}],"version-history":[{"count":7,"href":"https:\/\/bxta.com\/de\/wp-json\/wp\/v2\/posts\/576\/revisions"}],"predecessor-version":[{"id":3215,"href":"https:\/\/bxta.com\/de\/wp-json\/wp\/v2\/posts\/576\/revisions\/3215"}],"wp:attachment":[{"href":"https:\/\/bxta.com\/de\/wp-json\/wp\/v2\/media?parent=576"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bxta.com\/de\/wp-json\/wp\/v2\/categories?post=576"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bxta.com\/de\/wp-json\/wp\/v2\/tags?post=576"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}